RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
+40.44%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$3.16B
AUM Growth
+$3.16B
(+26%)
Cap. Flow
+$71.7M
Cap. Flow
% of AUM
2.27%
Top 10 Holdings %
Top 10 Hldgs %
29.57%
Holding
150
New
12
Increased
35
Reduced
32
Closed
19
Top Buys
| 1 |
Johnson & Johnson
JNJ
|
$73.2M |
| 2 |
Humana
HUM
|
$67.8M |
| 3 |
Aprea Therapeutics
APRE
|
$33.2M |
| 4 |
AXNX
Axonics, Inc. Common Stock
AXNX
|
$24.9M |
| 5 |
Acadia Pharmaceuticals
ACAD
|
$20.7M |
Top Sells
| 1 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
$49M |
| 2 |
MDCO
Medicines Co
MDCO
|
$41.8M |
| 3 |
AbbVie
ABBV
|
$39.8M |
| 4 |
Stryker
SYK
|
$38.7M |
| 5 |
Cigna
CI
|
$29M |
Sector Composition
| 1 | Healthcare | 90.33% |
| 2 | Consumer Staples | 0.66% |
| 3 | Consumer Discretionary | 0.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
UnitedHealth
UNH
$281B
| $174M | 5.49% | 591,000 | – | – |
|
2
Neurocrine Biosciences
NBIX
$13.8B
| $137M | 4.34% | 1,278,000 +45,500 | +4% | +$4.89M |
|
|
WCG
3
DELISTED
Wellcare Health Plans, Inc.
WCG
| $106M | 3.34% | 320,500 | – | – |
|
|
AMRN
4
Amarin Corp
AMRN
$311M
| $99.7M | 3.15% | 4,650,000 | – | – |
|
5
Intuitive Surgical
ISRG
$170B
| $90.2M | 2.85% | 152,500 | – | – |
|
|
6
Johnson & Johnson
JNJ
$427B
| $81.3M | 2.57% | 557,500 +501,500 | +896% | +$73.2M |
|
7
HCA Healthcare
HCA
$94.5B
| $69.1M | 2.18% | 467,500 | – | – |
|
|
8
Humana
HUM
$36.5B
| $67.8M | 2.14% | +185,000 | New | +$67.8M |
|
9
Encompass Health
EHC
$12.3B
| $56.5M | 1.78% | 815,000 | – | – |
|
10
Boston Scientific
BSX
$156B
| $54.3M | 1.71% | 1,200,000 +230,000 | +24% | +$10.4M |
|
11
Pacira BioSciences
PCRX
$1.2B
| $52.1M | 1.65% | 1,150,000 | – | – |
|
|
EPZM
12
DELISTED
Epizyme, Inc
EPZM
| $50.4M | 1.59% | 2,050,000 +199,900 | +11% | +$4.92M |
|
13
Teleflex
TFX
$5.59B
| $48.9M | 1.55% | 130,000 | – | – |
|
14
Insulet
PODD
$23.9B
| $44.6M | 1.41% | 260,500 | – | – |
|
15
Sarepta Therapeutics
SRPT
$1.78B
| $44.6M | 1.41% | 345,500 +8,000 | +2% | +$1.03M |
|
16
Vertex Pharmaceuticals
VRTX
$100B
| $44.4M | 1.4% | 203,000 | – | – |
|
17
Baxter International
BAX
$12.7B
| $43.9M | 1.39% | 525,000 +140,000 | +36% | +$11.7M |
|
18
Edwards Lifesciences
EW
$47.8B
| $42.8M | 1.35% | 183,500 | – | – |
|
19
iRhythm Technologies
IRTC
$5.46B
| $42.5M | 1.34% | 624,000 +69,000 | +12% | +$4.7M |
|
20
Alnylam Pharmaceuticals
ALNY
$58.5B
| $41.9M | 1.32% | 364,000 +33,500 | +10% | +$3.86M |
|
21
Penumbra
PEN
$10.6B
| $39.8M | 1.26% | 242,500 | – | – |
|
22
argenx
ARGX
$43.6B
| $39.7M | 1.26% | 247,500 +65,800 | +36% | +$10.6M |
|
23
Exact Sciences
EXAS
$8.98B
| $38.8M | 1.23% | 420,000 -11,750 | -3% | -$1.09M |
|
|
MRTX
24
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $38.7M | 1.22% | 300,000 +42,500 | +17% | +$5.48M |
|
25
Ardelyx
ARDX
$1.53B
| $36.4M | 1.15% | 4,850,000 +1,794,739 | +59% | +$13.5M |
|